ArticleMedical care2014
Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies.
Article in Medical care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 67 citations in OpenAlex.
- Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.Blood · 2018Trial
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis.Current oncology (Toronto, Ont.) · 2025Article
- Predictors and Drivers of End-of-Life Medicare Spending Among Older Adults with Solid Tumors: A Population-Based Study.Cancers · 2025Article
- Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases.Translational lung cancer research · 2024Article
- Predictors of high-intensity care at the end of life among older adults with solid tumors: A population-based study.Journal of geriatric oncology · 2024Article
- Association of cancer diagnosis with disability status among older survivors of colorectal cancer: a population-based retrospective cohort study.Frontiers in oncology · 2024Article
- Impact of functional disability on health-care use and medical costs among cancer survivors.JNCI cancer spectrum · 2023Article
- Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.The Journal of urology · 2023Article
- Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.Cancer reports (Hoboken, N.J.) · 2022Article
- Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer.Journal of thoracic disease · 2022Article
- Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy.Journal of geriatric oncology · 2021Article
- Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.Health services research · 2021Article
- Early Palliative Care Services and End-of-Life Care in Medicare Beneficiaries with Hematologic Malignancies: A Population-Based Retrospective Cohort Study.Journal of palliative medicine · 2021Article
- Measuring Frailty in Health Care Databases for Clinical Care and Research.Annals of geriatric medicine and research · 2020Review
- The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis.Journal of clinical pathways : the foundation of value-based care · 2020Article
- Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based studyLeukemia & lymphoma · 2020Article
- Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.JAMA network open · 2020Article
- Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.Cancer medicine · 2020Article
- Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer.Cancer · 2020Article
- Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.Leukemia & lymphoma · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundIn prior research, we developed a claims-based prediction model for poor patient disability status (DS), a proxy measure for performance status, commonly used by oncologists to summarize patient functional status and assess ability of a patient to tolerate aggressive treatment. In this study, we implemented and validated the DS measure in 4 cohorts of cancer patients: early and advanced non-small cell lung cancers (NSCLC), stage IV estrogen receptor-negative (ER-) breast cancer, and myelodysplastic syndromes (MDS). DATA AND
methodsSEER-Medicare data (1999-2007) for the 4 cohorts of cancer patients. Bivariate and multivariate logistic regression tested the association of the DS measure with designated cancer-directed treatments: early NSCLC (surgery), advanced NSCLC (chemotherapy), stage IV ER- breast cancer (chemotherapy), and MDS (erythropoiesis-stimulating agents). Treatment model fit was compared across model iterations.
resultsIn both unadjusted and adjusted results, predicted poor DS was strongly associated with a lower likelihood of cancer treatment receipt in all 4 cohorts [early NSCLC (N=20,280), advanced NSCLC (N=31,341), stage IV ER- breast cancer (N=1519), and MDS (N=6058)] independent of other patient, contextual, and disease characteristics, as well as the Charlson Comorbidity Index. Inclusion of the DS measure into models already controlling for other variables did not significantly improve model fit across the cohorts.
conclusionsThe DS measure is a significant independent predictor of cancer-directed treatment. Small changes in model fit associated with both DS and the Charlson Comorbidity Index suggest that unobserved factors continue to play a role in determining cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.